CINGW · Insider Trading
Cingulate Inc. Warrants
Every open-market purchase and sale reported by CINGW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Thomas Jeffrey Hargroves | Director | Buy | +97,276 | +$490.27K |
| 2026-05-08 | Raul R. Silva | EVP and CSO | A | +3,422 deriv. | — |
| 2026-03-11 | Matthew Brams | EVP and Chief Medical Officer | MIXED | +3,501 | — |
| 2026-03-11 | Raul R. Silva | EVP and CSO | MIXED | +2,698 | — |
| 2026-03-11 | Nilay Dahyabhai Patel | EVP, CLO and CCO | MIXED | +3,389 | — |
| 2026-03-11 | Jennifer L. Callahan | EVP and CFO | MIXED | +8,902 | — |
| 2026-03-11 | Shane J. Schaffer | Chief Executive Officer | MIXED | +3,903 | — |
| 2026-02-10 | Jennifer L. Callahan | SVP and CFO | Buy | +4,864 | +$24.51K |
| 2026-02-10 | Matthew Brams | EVP and Chief Medical Officer | Buy | +1,946 | +$9.81K |
| 2026-02-10 | Shane J. Schaffer | Chief Executive Officer | Buy | +6,809 | +$34.32K |
| 2026-02-10 | Peter J. Werth | Director | Buy | +19,455 | +$98.05K |
| 2026-01-05 | Raul R. Silva | EVP and CSO | A | +6,625 deriv. | — |
| 2025-11-10 | Bryan Wade Downey | Chief Commercial Officer | A | +30,000 deriv. | — |
| 2025-11-10 | Raul R. Silva | EVP and CSO | A | +7,334 deriv. | — |
| 2025-07-10 | Nilay Dahyabhai Patel | CLO and CCO | A | +30,000 deriv. | — |
| 2025-07-09 | Laurie Myers | EVP and COO | A | +31,000 deriv. | — |
| 2025-07-09 | Raul R. Silva | EVP and CSO | A | +51,500 deriv. | — |
| 2025-07-09 | Matthew Brams | EVP and Chief Medical Officer | A | +52,500 deriv. | — |
| 2025-07-09 | Jennifer L. Callahan | SVP and CFO | A | +64,500 deriv. | — |
| 2025-07-09 | Shane J. Schaffer | Chief Executive Officer | A | +199,500 deriv. | — |
| 2025-07-01 | Raul R. Silva | EVP and CSO | A | +2,000 deriv. | — |
| 2025-06-23 | Peter J. Werth | Director | A | +15,000 deriv. | — |
| 2025-06-23 | John A Roberts | Director | A | +15,000 deriv. | — |
| 2025-06-23 | Bryan Jay Lawrence | Director | A | +15,000 deriv. | — |
| 2025-06-23 | Jeffrey S Ervin | Director | A | +15,000 deriv. | — |
| 2025-02-20 | Shane J. Schaffer | Chief Executive Officer | A | +70,489 deriv. | — |
| 2025-02-20 | Matthew Brams | EVP and Chief Medical Officer | A | +17,630 deriv. | — |
| 2025-02-20 | Jennifer L. Callahan | SVP and CFO | A | +21,140 deriv. | — |
| 2025-02-20 | Laurie Myers | EVP and COO | A | +17,630 deriv. | — |
| 2025-02-20 | Raul R. Silva | EVP and CSO | A | +17,630 deriv. | — |
| 2025-01-22 | Jennifer L. Callahan | SVP and CFO | A | +11,539 deriv. | — |
| 2025-01-22 | Shane J. Schaffer | Chief Executive Officer | A | +27,638 deriv. | — |
| 2025-01-22 | Matthew Brams | EVP and Chief Medical Officer | A | +2,748 deriv. | — |
| 2025-01-22 | Raul R. Silva | EVP and CSO | A | +2,748 deriv. | — |
| 2025-01-22 | Laurie Myers | EVP and COO | A | +9,319 deriv. | — |
| 2025-01-07 | Raul R. Silva | EVP and CSO | A | +1,000 deriv. | — |
| 2025-01-07 | Matthew Brams | EVP and Chief Medical Officer | A | +1,000 deriv. | — |
| 2024-10-01 | Matthew Brams | EVP and Chief Medical Officer | A | +1,000 deriv. | — |
| 2024-10-01 | Raul R. Silva | EVP and CSO | A | +1,000 deriv. | — |
| 2024-08-19 | Laurie Myers | EVP and COO | Sell | −202 | −$841 |
| 2024-07-02 | Matthew Brams | EVP and Chief Medical Officer | A | +1,000 deriv. | — |
| 2024-07-02 | Raul R. Silva | EVP and CSO | A | +1,000 deriv. | — |
| 2024-06-13 | Matthew Brams | EVP and Chief Medical Officer | A | +63,324 deriv. | — |
| 2024-06-13 | Raul R. Silva | EVP and CSO | A | +63,324 deriv. | — |
| 2024-06-13 | Bryan Jay Lawrence | Director | A | +29,125 deriv. | — |
| 2024-06-13 | Shane J. Schaffer | Chief Executive Officer | A | +217,677 deriv. | — |
| 2024-06-13 | Jennifer L. Callahan | SVP and CFO | A | +94,986 deriv. | — |
| 2024-06-13 | Peter J. Werth | Director | A | +16,926 deriv. | — |
| 2024-06-13 | Laurie Myers | EVP and COO | A | +98,944 deriv. | — |
| 2024-06-13 | John A Roberts | Director | A | +29,750 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Peter J. Werth | Director | 117,541 | $1.18K |
| Thomas Jeffrey Hargroves | Director | 105,768 | $1.06K |
| Jennifer L. Callahan | EVP and CFO | 20,388 | $204 |
| Shane J. Schaffer | Chief Executive Officer | 17,210 | $172 |
| Matthew Brams | EVP and Chief Medical Officer | 9,182 | $92 |
| Raul R. Silva | EVP and CSO | 6,473 | $65 |
| Nilay Dahyabhai Patel | EVP, CLO and CCO | 3,389 | $34 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CINGW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.